[Congressional Bills 115th Congress]
[From the U.S. Government Publishing Office]
[S. 920 Introduced in Senate (IS)]
<DOC>
115th CONGRESS
1st Session
S. 920
To establish a National Clinical Care Commission.
_______________________________________________________________________
IN THE SENATE OF THE UNITED STATES
April 24, 2017
Mrs. Shaheen (for herself and Ms. Collins) introduced the following
bill; which was read twice and referred to the Committee on Health,
Education, Labor, and Pensions
_______________________________________________________________________
A BILL
To establish a National Clinical Care Commission.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``National Clinical Care Commission
Act''.
SEC. 2. NATIONAL CLINICAL CARE COMMISSION.
(a) Establishment.--There is hereby established, within the
Department of Health and Human Services, a National Clinical Care
Commission (in this section referred to as the ``Commission'') to
evaluate and make recommendations regarding improvements to the
coordination and leveraging of programs within the Department and other
Federal agencies related to awareness and clinical care for at least
one, but not more than two, complex metabolic or autoimmune diseases
resulting from issues related to insulin that represent a significant
disease burden in the United States, which may include complications
due to such diseases.
(b) Membership.--
(1) In general.--The Commission shall be composed of the
following voting members:
(A) The heads of the following Federal agencies and
departments, or their designees:
(i) The Centers for Medicare & Medicaid
Services.
(ii) The Agency for Healthcare Research and
Quality.
(iii) The Centers for Disease Control and
Prevention.
(iv) The Indian Health Service.
(v) The Department of Veterans Affairs.
(vi) The National Institutes of Health.
(vii) The Food and Drug Administration.
(viii) The Health Resources and Services
Administration.
(ix) The Department of Defense.
(x) The Department of Agriculture.
(xi) The Office of Minority Health.
(B) Twelve additional voting members appointed
under paragraph (2).
(2) Additional members.--The Commission shall include
additional voting members, as may be appointed by the
Secretary, with expertise in the prevention, care, and
epidemiology of any of the diseases and complications described
in subsection (a), including one or more such members from each
of the following categories:
(A) Physician specialties, including clinical
endocrinologists, that play a role in the prevention or
treatment of diseases and complications described in
subsection (a).
(B) Primary care physicians.
(C) Non-physician health care professionals.
(D) Patient advocates.
(E) National experts, including public health
experts, in the duties listed under subsection (c).
(F) Health care providers furnishing services to a
patient population that consists of a high percentage
(as specified by the Secretary) of individuals who are
enrolled in a State plan under title XIX of the Social
Security Act or who are not covered under a health plan
or health insurance coverage.
(3) Chairperson.--The members of the Commission shall
select a chairperson from the members appointed under paragraph
(2).
(4) Meetings.--The Commission shall meet at least twice,
and not more than four times, a year.
(5) Vacancies.--A vacancy on the Commission shall be filled
in the same manner as the original appointments.
(c) Duties.--The Commission shall evaluate and make
recommendations, as appropriate, to the Secretary of Health and Human
Services and Congress regarding--
(1) Federal programs of the Department of Health and Human
Services that focus on preventing and reducing the incidence of
the diseases and complications described in subsection (a);
(2) current activities and gaps in Federal efforts to
support clinicians in providing integrated, high-quality care
to individuals with the diseases and complications described in
subsection (a);
(3) the improvement in, and improved coordination of,
Federal education and awareness activities related to the
prevention and treatment of the diseases and complications
described in subsection (a), which may include the utilization
of new and existing technologies; and
(4) methods for outreach and dissemination of education and
awareness materials that--
(A) address the diseases and complications
described in subsection (a);
(B) are funded by the Federal Government; and
(C) are intended for health care professionals and
the public.
(d) Operating Plan.--Not later than 90 days after its first
meeting, the Commission shall submit to the Secretary of Health and
Human Services and the Congress an operating plan for carrying out the
activities of the Commission as described in subsection (c). Such
operating plan may include--
(1) a list of specific activities that the Commission plans
to conduct for purposes of carrying out the duties described in
each of the paragraphs in subsection (c);
(2) a plan for completing the activities;
(3) a list of members of the Commission and other
individuals who are not members of the Commission who will need
to be involved to conduct such activities;
(4) an explanation of Federal agency involvement and
coordination needed to conduct such activities;
(5) a budget for conducting such activities; and
(6) other information that the Commission deems
appropriate.
(e) Final Report.--By not later than 3 years after the date of the
Commission's first meeting, the Commission shall submit to the
Secretary of Health and Human Services and the Congress a final report
containing all of the findings and recommendations required by this
section.
(f) Sunset.--The Commission shall terminate 60 days after
submitting its final report, but not later than the end of fiscal year
2021.
<all>